

# [Cellular and molecular mechanisms of motor neuron death in amyotrophic lateral sc...](https://assignbuster.com/cellular-and-molecular-mechanisms-of-motor-neuron-death-in-amyotrophic-lateral-sclerosis-a-perspective/)

[Health & Medicine](https://assignbuster.com/essay-subjects/health-n-medicine/)

Amyotrophic lateral sclerosis (ALS), which was described since 1869 by Jean Martin Charcot, is a devastating neurodegenerative disease characterized by the selective and progressive loss of upper and lower motor neurons of the cerebral cortex, brainstem and the spinal cord. The result of this loss is a progressive and irreversible paralysis leading to a complete incapacity of movements and finally to respiratory failure, but the cognitive functions are not affected and is not merely the result of aging because may occur at young adult ages. There is still no treatment, prevention or reliable biomarkers of ALS and it is clear that this could only be accomplished, as for other neurodegenerative diseases, through the knowledge of the cellular and molecular pathophysiological mechanisms involved. Research on such mechanisms is, therefore, essential. Although progress in neurochemical, physiological, genetic and clinical investigations in the last decades has identified several cellular processes and mechanisms that seem to be involved in the neuronal death, such as glutamate receptors-mediated excitotoxicity, disruption of spinal inhibitory circuits, inflammatory events, axonal transport deficits, oxidative stress, mitochondrial dysfunction, energy failure, intracellular Ca 2+ dishomeostasis, protein aggregation and misfolding, changes in gene expression, astrocytes alterations, and non-cell autonomous toxic factors, the understanding of the origin and temporal progress of the disease is still incomplete and insufficient. Clearly, there is a need of further experimental models and approaches to discern the importance of such mechanisms and to discover the factors that determine the selective death of motor neurons characteristic of ALS, in contrast to other neurodegenerative diseases such as Parkinson's and Alzheimer's disease in which other neuronal types located in other CNS regions are predominantly affected.

The only known cause of the disease is associated with genetic mutations, mainly in the gene encoding superoxide dismutase 1 (SOD1) which is the most frequent case of familial ALS (FALS), representing about 20% of cases of FALS, albeit over one hundred mutations have been described in FALS. In contrast, there is no known cause of the sporadic form of ALS (SALS), that comprises > 90% of all cases, although several other mutations have recently been identified also in SALS. Both ALS types show similar histopathological and clinical characteristics, and in spite of numerous investigations using tissue from ALS patients and relevant advances in the design of several experimental models of motor neuron degeneration, it has not been possible to establish a clear cause-effect relationship regarding the loss of motor neurons or the motor alterations characteristic of the disease, such as fasciculations, spasticity, and progressive paralysis.

Studies *in vitro* in cell cultures, tissue slices or organotypic preparations have given useful information regarding the cellular and molecular mechanisms of motor neuron death. However, except for transgenic rodents expressing mutant forms of human SOD1 (mSOD1), which are the most extensively used model *in vivo* in spite of the low frequency of FALS as compared to SALS, experiments in living animals are scarce. These models should reflect more closely the situation in the human disease, provided that the symptoms and their development during time mimics as close as possible those of the human disease. It is therefore necessary to correlate the experimental findings *in vitro* with those *in vivo* , as well as those obtained in genetic models with those in non-genetic models, in order to design and test therapeutic strategies based on the results obtained. The aim of the original research articles and reviews of this Research Topic is to contribute to the progress in this important field.

Genetic alterations, including epigenetic and gene expression changes in both neurons and glial cells, mainly astrocytes, as well as studies *ex vivo* of nervous and muscular tissue from ALS patients and from mutant SOD1 transgenic mice, constitute the majority of the articles of this Research Topic. Such changes have been studied in whole tissue, microdissected isolated cells and subcellular fractions, mainly mitochondria, using several molecular biology techniques, not only in the CNS but also in muscle of mSOD mice, and have shown that there is a large variety of alterations in gene expression. These results are the subject of the articles by [Heath et al. (2013)](#B7) ; [Crippa et al. (2013)](#B2) ; [de Oliveira et al. (2013)](#B3) , and [Wong et al. (2013)](#B18) , which amply cover the literature on this subject and also provide new data, such as the relation of some of these genetic alterations with autophagy, epigenetic changes of mitochondrial DNA in the spinal cord and in muscle, and comparative analysis of early and late gene expression changes.

The role of astrocytes and microglia from mSOD mice in non-cell autonomous processes, including the release of toxic factors, is studied by [Rojas et al. (2014)](#B12) and [Trias et al. (2013)](#B17) , with a useful *ex vivo* approach. Related studies by [Staats et al. (2013)](#B15) and [Bowerman et al. (2013)](#B1) show the involvement of microglia and neuroimmunological events in the progress of ALS and suggest possible therapeutic strategies. The molecular modifications of mSOD1 protein, and how such alterations, like oxidation, aggregation or misfolding, result in its toxicity, are reviewed by [Furukawa (2013)](#B4) ; [Rotunno and Bosco (2013)](#B13) , and [Ogawa and Furukawa (2014)](#B11) . Again in mSOD1 mice but with a different approach, [Mòdol et al. (2014)](#B10) show a possible role of the potassium chloride cotransporter 2 in spasticity, including results on the role of spinal inhibitory interneurons.

A partial protective effect of the NMDA receptor antagonist gacyclidine on the motor deficits in mSOD1 mice is shown by [Gerber et al. (2013)](#B6) , and the role of trophic factors in the modulation of motor neurons activity as well as their protective effect in several models of ALS, is reviewed by [Tovar-y-Romo et al. (2014)](#B16) and [Lladó et al. (2013)](#B9) . It is emphasized in particular the potent protective action of vascular endothelial growth factor (VEGF). Other potential protective agents, reviewed by [Lazo-Gómez et al. (2013)](#B8) , are activators or inhibitors of histone deacetylases, enzymes that regulate gene expression and may be involved in motor neuron degeneration.

A general panorama of the role of lipids in ALS is presented by [Schmitt et al. (2014)](#B14) , with emphasis on energy and signaling mechanisms. In a more systemic approach, [Garbuzova-Davis and Sanberg (2014)](#B5) review the vascular changes that may alter blood brain barrier and thus be involved in the pathogenesis of ALS, as compared to the transgenic rodent models.

The large amount of information contained in this Research Topic, in both the comprehensive reviews and the original research articles, reflect the considerable advances made but at the same time the necessity for new experimental models and approaches for gaining clearer responses to several still unresolved questions, such as the following: why the clinical manifestations of motor neuron death in both FALS and SALS appear in young adulthood but are not age-related, particularly the former, in spite of the fact that genetic alterations are present since the beginning of individual life? Why the motor neuron degeneration progresses rapidly after the initial symptoms appear? What is the cause of SALS? It is now clear that the loss of motor neurons in ALS is multifactorial, but many of the deleterious factors seem to occur also in other neurodegenerative diseases like Parkinson's and Alzheimer' disease; then, maybe the crucial question to be answered is: what determines the predominant, if not totally selective characteristic death of motor neurons in ALS, sparing other neuronal types?

In spite of these unsolved questions, it is clear that the available information permits the design and testing of diverse therapeutic strategies that have already shown valuable results in delaying or preventing neuronal death in experimental models, for example the administration of VEGF. However, the translation of possibly effective treatments from experimental procedures to ALS patients represents different problems, such as the routes, doses and timing of administration and the potential undesirable collateral effects. Because we have no indication or biomarker of the susceptibility to ALS and of when will it manifest, it is extremely difficult to prevent or treat the disease. When symptoms have already started and the diagnosis is made it is probably too late to impede the progression of neuronal degeneration. A verifiable resolution of the above questions seems a requisite for efficient and reliable treatments or prevention of this dreadful disease.

## Conflict of Interest Statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Acknowledgments

This work was supported by Consejo Nacional de Ciencia y Tecnología (project 128229) and Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (UNAM) (IN201013).

## References

Bowerman, M., Vincent, T., Scamps, F., Perrin, F. E., Camu, W., and Raoul, C. (2013). Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis. *Front. Cell. Neurosci* . 7: 214. doi: 10. 3389/fncel. 2013. 00214

Crippa, V., Boncoraglio, A., Galbiati, M., Aggarwal, T., Rusmini, P., Giorgetti, E., et al. (2013). Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. *Front. Cell. Neurosci* . 7: 234. doi: 10. 3389/fncel. 2013. 00234

de Oliveira, G. P., Alves, C. J., and Chadi, G. (2013). Early gene expression changes in spinal cord from SOD1 G93A Amyotrophic Lateral Sclerosis animal model. *Front. Cell. Neurosci* . 7: 216. doi: 10. 3389/fncel. 2013. 00216

Furukawa, Y. (2013). Redox environment is an intracellular factor to operate distinct pathways for aggregation of Cu, Zn-superoxide dismutase in amyotrophic lateral sclerosis. *Front. Cell. Neurosci* . 7: 240. doi: 10. 3389/fncel. 2013. 00240

Garbuzova-Davis, S., and Sanberg, P. R. (2014). Blood–CNS barrier impairment in ALS patients versus an animal model. *Front. Cell. Neurosci* . 8: 21. doi: 10. 3389/fncel. 2014. 00021

Gerber, Y. N., Privat, A., and Perrin, F. E. (2013). Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis. *Front. Cell. Neurosci* . 7: 280. doi: 10. 3389/fncel. 2013. 00280

Heath, P. R., Kirby, J., and Shaw, P. J. (2013). Investigating cell death mechanisms in amyotrophic lateral sclerosis using transcriptomics. *Front. Cell. Neurosci* . 7: 259. doi: 10. 3389/fncel. 2013. 00259

Lazo-Gómez, R., Ramírez-Jarquín, U. N., Tovar-y-Romo, L. B., and Tapia, R. (2013). Histone deacetylases and their role in motor neuron degeneration. *Front. Cell. Neurosci* . 7: 243. doi: 10. 3389/fncel. 2013. 00243

Lladó, J., Tolosa, L., and Olmos, G. (2013). Cellular and molecular mechanisms involved in the neuroprotective effects of VEGF on motoneurons. *Front. Cell. Neurosci* . 7: 181. doi: 10. 3389/fncel. 2013. 00181

Mòdol, L., Mancuso, R., Alé, A., Francos-Quijorna, I., and Navarro, X. (2014). Differential effects on KCC2 expression and spasticity of ALS and traumatic injuries to motoneurons. *Front. Cell. Neurosci* . 8: 7. doi: 10. 3389/fncel. 2014. 00007

Ogawa, M., and Furukawa, Y. (2014). A seeded propagation of Cu, Zn-superoxide dismutase aggregates in amyotrophic lateral sclerosis. *Front. Cell. Neurosci* . 8: 83. doi: 10. 3389/fncel. 2014. 00083

Rojas, F., Cortes, N., Abarzua, S., Dyrda, A., and van Zundert, B. (2014). Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. *Front. Cell. Neurosci* . 8: 24. doi: 10. 3389/fncel. 2014. 00024

Rotunno, M. S., and Bosco, D. A. (2013). An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis. *Front. Cell. Neurosci* . 7: 253. doi: 10. 3389/fncel. 2013. 00253

Schmitt, F., Hussain, G., Dupuis, L., Loeffler, J.-P., and Henriques, A. (2014). A plural role for lipids in motor neuron diseases: energy, signaling and structure. *Front. Cell. Neurosci* . 8: 25. doi: 10. 3389/fncel. 2014. 00025

Staats, K. A., Schönefeldt, S., Van Rillaer, M., Van Hoecke, A., Van Damme, P., Robberecht, W., et al. (2013). Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. *Front. Cell. Neurosci* . 7: 249. doi: 10. 3389/fncel. 2013. 00249

Tovar-y-Romo, L. B., Ramírez-Jarquín, U. N., Lazo-Gómez, R., and Tapia, R. (2014). Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy. *Front. Cell. Neurosci* . 8: 61. doi: 10. 3389/fncel. 2014. 00061

Trias, E., Díaz-Amarilla, P., Olivera-Bravo, S., Isasi, E., Drechsel, D. A., Lopez, N., et al. (2013). Phenotypic transition of microglia into astrocyte-like cells associated with disease onset in a model of inherited ALS. *Front. Cell. Neurosci* . 7: 274. doi: 10. 3389/fncel. 2013. 00274

Wong, M., Gertz, B., Chestnut, B. A., and Martin, L. J. (2013). Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. *Front. Cell. Neurosci* . 7: 279. doi: 10. 3389/fncel. 2013. 00279